US EditionAtlas Private Wealth Advisors Reduces Position in Johnson & Johnson $JNJ
Atlas Private Wealth Advisors sold 8,757 Johnson & Johnson shares in Q3, reducing its stake by 63.3% to 5,077 shares worth $941,000, per SEC filings.
- Institutional investors reshuffled Johnson & Johnson holdings, with CA trimming its stake by 1.0% and Welch & Forbes LLC reducing theirs by 1.6% in the third quarter.
- After reporting quarterly earnings of $2.46 EPS and $24.56 billion revenue, Johnson & Johnson declared a $1.30 quarterly dividend with record date Tuesday, February 24th and payment Tuesday, March 10th.
- Market data show Johnson & Johnson stock opened at $227.00 t on Friday, with a 50-day moving average of $210.72 and a 12-month high near $230.00.
- Funds own roughly 69.55% of JNJ, with Everett Harris & Co. CA holding $88,901,000 and JNJ representing about 1.3% of Winnow Wealth LLC’s portfolio.
- A U.S. judge dismissed a fraud claim tied to talc bankruptcy litigation, removing a legal overhang, while Johnson & Johnson set FY2026 guidance at 11.430–11.630 EPS, with analysts forecasting 10.58 EPS.
3 Articles
3 Articles
Welch & Forbes LLC Cuts Holdings in Johnson & Johnson $JNJ
Welch & Forbes LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 675,855 shares of the company’s stock after selling 11,287 shares during the quarter. Johnson & Johnson accounts for about 1.5% of Welch & Forbes LLC’s investment portfolio, making the stock its 14th biggest holding. Welch &…
Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion
New York, Feb 1, 2026, 10:36 EST — Market closed Johnson & Johnson (JNJ.N) shares closed Friday nearly flat, slipping just 0.01% to $227.25. The stock moves into Monday following a positive nod from European Medicines Agency advisers, who supported expanding the use of its prostate-cancer drug Akeega. (European Medicines Agency (EMA)) Why it matters now: Johnson & Johnson is relying on oncology and newer specialty drugs to sustain growth as its …
Banyan Capital Management Inc. Buys Shares of 3,853 Johnson & Johnson $JNJ
Banyan Capital Management Inc. acquired a new position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,853 shares of the company’s stock, valued at approximately $714,000. Johnson & Johnson comprises approximately 0.3% […]
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
